Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders
Frontiers in Cellular and Infection Microbiology · 2024
DOI: 10.3389/fcimb.2024.1397743 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Lina Fan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Tianjin Second People's Hospital, Tianjin, China. Hauptthemen laut MEDLINE: HIV Infections, Immune Reconstitution, Viral Load, CD4-Positive T-Lymphocytes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Incomplete immune recovery in people living with HIV/AIDS (PLWHA) remains an important clinical challenge with the lack of an effective strategy currently available to restore their T-cell immune response. This study aimed to evaluate the effect of Albuvirtide (ABT) on immune recovery in immunological non-responders (INRs) and attempted to explore potential mechanisms of ABT on the functionality of immune cells.
Methods
In this prospective, open-label, controlled clinical study, participants with incomplete immune reconstitution (continuous ART over 5 years and CD4 + T lymphocyte absolute count of <500 cells/µl or ART for 2–5 years and CD4 + T cell count of <200 cells/µl with undetectable viral load) were received intensive treatment with ABT or maintained on the original ART regimen at a ratio of 1:1. Immune response and safety were examined within 24 weeks. In the cytological study, T subsets, cell apoptosis and cell autophagy were analyzed using immunofluorescence staining and flow cytometry from 25 blood specimens.
Results
Both groups (n=25 each) were comparable in age, gender, and ART duration. At week 12, CD4 + T cell count increased significantly in the intensive ABT group compared with control group (the change from baseline in CD4 + T cell count: 45 vs. -5 cells/µL, p <0.001). After ABT discontinuation, CD4 + T cell counts remained significantly higher in the intensive ABT group at week 24 (55 vs. -5 cells/µL, p =0.012). In laboratory analysis, naïve CD4 + T cell amounts were lowest among participants with unsatisfactory immune response (uIR) to ABT ( p =0.001). The proportion of caspase 3 + CD45RA + CD31 + CD4 + T cells was significantly lower in participants with satisfactory immune response (sIR) to ABT ( p <0.05).
Conclusion
Significant CD4 + T cell count increase suggests ABT enhances immune function in INRs which may be attributed to its antiviral properties as well as its ability to increase thymic cell output and decrease cell apoptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Tianjin Second People's Hospital, Tianjin, China.
- Tianjin Institute of Hepatology, Tianjin Second People's Hospital, Tianjin, China.
- Tianjin Medical University, Tianjin, China.
- Medical Affairs Department, Frontier Biotechnologies Inc, Nanjing, Jiangsu, China.
- Department of Pathology, Tianjin Second People's Hospital, Tianjin, China.
- Department of Infectious Diseases, Henan Infectious Diseases Hospital, Zhengzhou, Henan, China.
Zitieren
APA
Fan, L., Hu, Y., Li, R., Ding, J., Liu, Y., Yu, S., Hu, M., Su, R., Li, Y., Yu, A., Xie, D., Zhao, Q., & Ma, P. (2024). Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1397743
Vancouver
Fan L, Hu Y, Li R, Ding J, Liu Y, Yu S, et al. Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1397743
BibTeX
@article{Fan2024,
author = {Fan, Lina and Hu, Yue and Li, Rui and Ding, Jiaqi and Liu, Yuantao and Yu, Shuchang and Hu, Min and Su, Rui and Li, Yangyang and Yu, AiPing and Xie, Dong and Zhao, Qingxia and Ma, Ping},
title = {Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
doi = {10.3389/fcimb.2024.1397743}
}
EUVIMED